What is Vaxcyte, Inc.'s other commercial liabilities?

Vaxcyte, Inc. (PCVX) reported other commercial liabilities of $30.25M in Q1 2026.

How has Vaxcyte, Inc.'s other commercial liabilities changed year-over-year?

Vaxcyte, Inc.'s other commercial liabilities increased by 16.1% year-over-year, from $26.04M to $30.25M.

What is the long-term trend for Vaxcyte, Inc.'s other commercial liabilities?

Over 5 years (2020 to 2025), Vaxcyte, Inc.'s other commercial liabilities has grown at a 52.5% compound annual growth rate (CAGR), from $3.77M to $31.07M.

Vaxcyte, Inc. PCVX Other Commercial Liabilities

Other Commercial Liabilities at other companies

ModernaMRNA

——

ImmunityBio, Inc.IBRX

——

Vertex PharmaceuticalsVRTX

——

Other financials

Income statement

See full

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

See full

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

See full

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

See full

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

See full

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vaxcyte, Inc.'s other commercial liabilities?: Vaxcyte, Inc. (PCVX) reported other commercial liabilities of $30.25M in Q1 2026.
How has Vaxcyte, Inc.'s other commercial liabilities changed year-over-year?: Vaxcyte, Inc.'s other commercial liabilities increased by 16.1% year-over-year, from $26.04M to $30.25M.
What is the long-term trend for Vaxcyte, Inc.'s other commercial liabilities?: Over 5 years (2020 to 2025), Vaxcyte, Inc.'s other commercial liabilities has grown at a 52.5% compound annual growth rate (CAGR), from $3.77M to $31.07M.